Cargando…
Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study
OBJECTIVES: Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the SARS-CoV-2 infection, extant research in adverse reactions using real-world data of various sociodemographic characteristics is scant. ME...
Autores principales: | Chan, Edward Wai Wa, Leung, Miriam Tim Yin, Lau, Lauren Ka Wun, Leung, Janice, Lum, Dawn, Wong, Rosa Sze-Man, Li, Xue, Chui, Celine Sze Ling, Wan, Eric Yuk Fai, Wong, Carlos King Ho, Chan, Esther Wai Yin, Ip, Patrick, Wong, Ian Chi Kei, Lai, Francisco Tsz Tsun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710238/ https://www.ncbi.nlm.nih.gov/pubmed/34965462 http://dx.doi.org/10.1016/j.ijid.2021.12.354 |
Ejemplares similares
-
Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022) -
Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
por: Joseph, Gili, et al.
Publicado: (2022) -
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
Publicado: (2021) -
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021) -
Pfizer-BioNTech COVID-19 vaccine safe in children
Publicado: (2022)